Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.44 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.34 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822574 | 0.78 | CXCR2 (0.68) | CXCR2CXCR1PTGS1PTGS2MT-CO2 | |
| SCHEMBL1820336 | 0.77 | PTGS1 (0.53) | CXCR2CXCR1PTGS1PTGS2MT-CO2 | |
| SCHEMBL24991968 | 0.76 | CXCR2 (0.54) | CXCR2CXCR1PTGS1PTGS2AKR1C3 | |
| SCHEMBL29960316 | 0.76 | CXCR2 (0.54) | CXCR2CXCR1PTGS1PTGS2AKR1C3 | |
| SCHEMBL16219340 | 0.76 | CXCR2 (0.48) | CXCR2CXCR1PTGS1PTGS2APP | |
| SCHEMBL16207566 | 0.76 | CXCR2 (0.48) | CXCR2CXCR1PTGS1PTGS2APP | |
| SCHEMBL17831703 | 0.74 | CXCR2 (0.46) | CXCR2CXCR1PTGS1PTGS2MT-CO2 | |
| SCHEMBL2124984 | 0.74 | MT-CO2 (0.44) | PTGS1PTGS2MAOBMT-CO2APP | |
| SCHEMBL2126332 | 0.73 | HSP90AB1 (0.45) | CXCR2 | |
| SCHEMBL777316 | 0.71 | HTR1A (0.34) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-8188092-B2 | Substituted pyrazines as DGAT-1 inhibitors | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-8188092-B2 | Substituted pyrazines as DGAT-1 inhibitors | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-8188092-B2 | Substituted pyrazines as DGAT-1 inhibitors | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| EP-2443096-A1 | PYRAZINE CARBOXAMIDES AS INHIBITORS OF DGAT1 | AstraZeneca AB (SE) | 2012-04-25 | — | — | EP | disclosed |
| US-20100324068-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324068-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324068-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | US | disclosed |
| WO-2010146395-A1 | PYRAZINE CARBOXAMIDES AS INHIBITORS OF DGAT1 | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010146395-A1 | PYRAZINE CARBOXAMIDES AS INHIBITORS OF DGAT1 | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324068-A1 | CHEMICAL COMPOUNDS 785 | GPBAR1, DGAT1, GPR119 | CXCR2 1382/4885CXCR1 671/4885PTGS1 2663/4885 |
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | DGAT1, DGAT2, SLC5A1 | CXCR2 3040/4885CXCR1 2512/4885PTGS1 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.